Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2

Conditions

Neuroendocrine Tumors 532Pituitary Neoplasms 187Multiple Endocrine Neoplasia Type 1 187Thyroid Cancer, Papillary 178Pheochromocytoma 153Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Paraganglioma 99Carcinoid Tumor 99Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Carcinoma, Medullary 59Gastro-enteropancreatic neuroendocrine tumor 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Interventions

AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Prostate Cancer × Endocrine × Clear all
NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

NCT07024277 2025-06-17

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Not yet recruiting
60 enrolled
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡